Earnings GuidanceCorMedix raised its Q2 net sales guidance to $35–40M, meaningfully improving analyst's near-term confidence in the durability of the launch and positions CRMD as a more visible and executable commercial growth story.
Market ReactionCRMD shares traded up around +21% as this validates DefenCath’s commercial momentum and de-risks broader implementation scenarios.
Product AdoptionThe updated guidance follows a significantly broader-than-expected implementation of DefenCath with its Large Dialysis Organization partner, now set to begin rollout and targeting a 6,000-patient annualized run rate.